Supernus Pharmaceuticals
Yahoo Finance • 3 days ago
Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks
Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks Let's dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season. Looking ahead, t... Full story
Yahoo Finance • 9 days ago
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
Reflecting On Branded Pharmaceuticals Stocks' Q2 Earnings: Corcept (NASDAQ:CORT) Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at Corcept (NASDAQ:CORT) and its... Full story
Yahoo Finance • 11 days ago
1 Healthcare Stock with Exciting Potential and 2 We Ignore
1 Healthcare Stock with Exciting Potential and 2 We Ignore Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their... Full story
Yahoo Finance • 25 days ago
Supernus and Indivior merge to create scaled, CNS-focused entity
Supernus Pharmaceuticals and Indivior Pharmaceuticals are joining forces to create a diversified and scaled biopharmaceutical company focused on the central nervous system (CNS). Through this all-stock merger, which is expected to generat... Full story
Yahoo Finance • 25 days ago
Stocks Settle Sharply Higher as Middle East Tensions Ease
The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.48%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +1.32%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.78%. September E-mini S&P futures (ESU26) rose +1.49%, and Sep... Full story
Yahoo Finance • 25 days ago
Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story
Yahoo Finance • 26 days ago
Stocks Rally on Easing Geopolitical Risks and US Economic Strength
The S&P 500 Index ($SPX) (SPY) today is up +1.18%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.081%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.40%. September E-mini S&P futures (ESU26) are up +1.11%, and September E-mini... Full story
Yahoo Finance • 26 days ago
Supernus jumps premarket on merger deal; GameStop drops
Investing.com - U.S. stock index futures advanced on Monday after President Donald Trump said negotiations with Iran were set to begin this week, easing geopolitical concerns that had rattled markets in recent weeks, while technology stock... Full story
Yahoo Finance • last month
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
ROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, t... Full story
Yahoo Finance • last month
1 Growth Stock to Stash and 2 We Turn Down
1 Growth Stock to Stash and 2 We Turn Down Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. Lu... Full story
Yahoo Finance • 2 months ago
Branded Pharmaceuticals Stocks Q1 Teardown: Zoetis (NYSE:ZTS) Vs The Rest
Branded Pharmaceuticals Stocks Q1 Teardown: Zoetis (NYSE:ZTS) Vs The Rest Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let's have a look at Zoetis (NYSE:ZTS) and its peers. Lo... Full story
Yahoo Finance • 2 months ago
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead Over the last six months, Supernus Pharmaceuticals's shares have sunk to $43.79, producing a disappointing 9.4% loss - a stark contrast to the S&P 500's 9.3% gain. This might have investo... Full story
Yahoo Finance • 3 months ago
3 Growth Stocks We Approach with Caution
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. Luckily for you, our job at StockStory is to h... Full story
Yahoo Finance • 4 months ago
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, an... Full story
Yahoo Finance • 4 months ago
Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Jazz Pharmaceuticals (NASDAQ:JAZZ) and the best and worst performers in the pharma... Full story
Yahoo Finance • 5 months ago
3 Unprofitable Stocks We Think Twice About
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. A lack of profits can lead to trouble, but... Full story
Yahoo Finance • 6 months ago
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
Supernus Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.1%. The stock now trades at $53.23, marking a 17.1% gain. This was partly thanks to its solid quarterly results, and th... Full story
Yahoo Finance • 6 months ago
Supernus Pharmaceuticals to Participate in March Investor Conferences
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, a... Full story
Yahoo Finance • 8 months ago
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back
Key Points Aristotle Capital Boston sold 503,122 shares of Supernus Pharmaceuticals in the third quarter. The move contributed to a net position change of about $10.9 million from the previous quarter. As of September 30, Aristotle Capita... Full story
Yahoo Finance • 9 months ago
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, a... Full story